GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (NAS:CNTX) » Definitions » Interest Coverage

CNTX (Context Therapeutics) Interest Coverage : N/A (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Context Therapeutics's Operating Income for the three months ended in Mar. 2025 was $-5.53 Mil. Context Therapeutics's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Context Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Context Therapeutics's Interest Coverage or its related term are showing as below:


CNTX's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Context Therapeutics Interest Coverage Historical Data

The historical data trend for Context Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Context Therapeutics Interest Coverage Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
Get a 7-Day Free Trial - - No Debt No Debt N/A

Context Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt N/A N/A N/A

Competitive Comparison of Context Therapeutics's Interest Coverage

For the Biotechnology subindustry, Context Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Context Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Context Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Context Therapeutics's Interest Coverage falls into.


;
;

Context Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Context Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Context Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-29.92 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.11 Mil.

GuruFocus does not calculate Context Therapeutics's interest coverage with the available data.

Context Therapeutics's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, Context Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-5.53 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.08 Mil.

GuruFocus does not calculate Context Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Context Therapeutics  (NAS:CNTX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Context Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Context Therapeutics Business Description

Traded in Other Exchanges
Address
2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Executives
Martin A. Lehr director, officer: Chief Executive Officer 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Jennifer Lynn Minai-azary officer: Chief Financial Officer 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Alex C. Levit officer: Chief Legal Officer, Corp. Sec 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Tarek Sahmoud officer: Chief Medical Officer 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jennifer Evans Stacey director AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Linda West director C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Evan G. Dick officer: SVP of R&D 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
William F. Rencher officer: Head of CMC and Regulatory 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104